1
|
Lapierre A, Hennequin C, Beneux A, Belhomme S, Benziane N, Biston MC, Crehange G, de Crevoisier R, Dumas JL, Fawzi M, Lisbona A, Pasquier D, Pelissier S, Graff-Cailleaud P, Pommier P, Sargos P, Simon JM, Supiot S, Tantot F, Chapet O. Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group. Crit Rev Oncol Hematol 2022; 173:103661. [PMID: 35341986 DOI: 10.1016/j.critrevonc.2022.103661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 01/25/2022] [Accepted: 03/21/2022] [Indexed: 10/18/2022] Open
Abstract
Stereotactic body radiotherapy (SBRT) has become treatment option for localized prostate cancer but the evidence base remains incomplete. Several clinical studies, both prospective and retrospective, have been published. However, treatment techniques, target volumes and dose constraints lack consistency between studies. Based on the current available literature, the French Genito-Urinary Group (GETUG) suggests that.
Collapse
Affiliation(s)
- Ariane Lapierre
- Ariane Lapierre: Département of de radiothérapie oncologie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université de Lyon, 69000 Lyon, France
| | - Christophe Hennequin
- Christophe Hennequin: Department of Radiation Oncology, Hôpital Saint-Louis, 75475, Paris, France
| | - Amandine Beneux
- Amandine Beneux: Service de Physique Médicale et de Radioprotection, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France
| | - Sarah Belhomme
- Sarah Belhomme: Radiation Oncology Department, Bergonie Institute, 229, cours de l'Argonne, 33076 Bordeaux Cedex, France
| | - Nicolas Benziane
- Nicolas Benziane: Radiation Oncology Department, Bergonie Institute, 229, cours de l'Argonne, 33076 Bordeaux Cedex, France
| | - Marie-Claude Biston
- Marie-Claude Biston: Léon Bérard Cancer Center, University of Lyon, France; Université de Lyon, CREATIS, CNRS UMR5220, Inserm U1044, INSA, Lyon, France
| | - Gilles Crehange
- Gilles Crehange: Département de radiothérapie oncologique, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - Renaud de Crevoisier
- Renaud de Crevoisier: Département de Radiothérapie, Centre Eugène Marquis, Rennes
| | - Jean-Luc Dumas
- Jean-luc Dumas: Institut Curie, Radiotherapy department / Medical physics, 26 rue d'Ulm, 75005 PARIS cedex, France
| | - Maher Fawzi
- Maher Fawzi: Institut Curie, Site Saint Cloud, Service de Radiotherapie, 35, rue Dailly 92210 Saint Cloud
| | - Albert Lisbona
- Albert Lisbona: Medical Physics Department Institut de Cancérologie de l'Ouest, Bd J. Monod, 44805 Saint Herblain France
| | - David Pasquier
- David Pasquier: Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille; CRIStAL UMR 9189, Lille University
| | | | - Pierre Graff-Cailleaud
- Pierre Graff-Cailleaud: University Institute of Cancer Toulouse-Oncopôle, Toulouse, France
| | - Pascal Pommier
- Pascal Pommier: Radiotherapy Department, Centre Léon Bérard, Lyon, France
| | - Paul Sargos
- Paul Sargos: Radiation Oncology Department, Bergonie Institute, Bordeaux, France
| | - Jean-Marc Simon
- Jean-Marc Simon: Department of Radiotherapy, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
| | - Stéphane Supiot
- Stéphane Supiot: Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, St-Herblain, France
| | | | - Olivier Chapet
- Département of de radiothérapie oncologie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université de Lyon, 69000 Lyon, France
| |
Collapse
|
2
|
Ramezani Farkhani R, Gholamhosseinian H, Anvari K, Forghani MN. Assessment of Thyroid Lobe Dose in Breast Cancer Intraoperative Radiotherapy. J Biomed Phys Eng 2021; 11:55-60. [PMID: 33564640 PMCID: PMC7859381 DOI: 10.31661/jbpe.v0i0.2001-1046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Accepted: 03/08/2020] [Indexed: 11/20/2022]
Abstract
Background: Breast cancer is the most common cancer among women. Considering the fact that a high dose is delivered in a single fraction of IORT, the evaluation of the dose at sensitive organs like thyroid is necessary. Objective: The current study has aimed to evaluate the received dose to thyroid lobes in the breast IORT technique. Material and Methods: A total of 49 women with breast cancer undergoing IORT were enrolled in this cross-sectional study with census sampling. Immediately after tumor resection, a single dose of 20 Gray at the applicator surface was delivered using 50KV X-ray by an Intrabeam machine. The thyroid dose was detected using thermoluminescent detectors (TLD) 100 at the mid-thyroid line, left and right lobes. Results: The dose at the right and left lobes of the thyroid gland as well as the mid-thyroid line was found to be 40.18±35.44 mGy, 35.50±27.32 mGy, and 40.61±32.47 mGy, respectively. The right lobe received a significantly higher absorbed dose compared to the left lobe when the right breast was under IORT treatment. The same trend was seen with the left lobe and left breast under IORT treatment (P=0.0001 and P=0.018, respectively). The applicator size showed non-significant effects on the absorbed dose at the thyroid gland. Also, the applicator depth had a non-significant inverse effect on thyroid dose. Conclusion: According to our findings, the absorbed dose at each thyroid lobe depends on the under-treatment side as well as the applicator size and depth (applicator upper surface distance from the skin).
Collapse
Affiliation(s)
- R Ramezani Farkhani
- MSc, Department of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - H Gholamhosseinian
- PhD, Department of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - K Anvari
- MD, Department of Radiotherapy & Oncology, Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
| | - M N Forghani
- MD, Department of General Surgery, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|